HIP1-ALK–Rearranged Lung Cancer in a Young Adult With BRAF V600E Mutation Detected After ALK Tyrosine Kinase Inhibitor Therapy: A Case Report

Aiko Ogimoto, MD; Naoko Katsurada, MD, PhD; Atsuhiko Yatani, MD; Chihiro Mimura, MD; Masatsugu Yamamoto, MD, PhD; Motoko Tachihara, MD, PhD

JTO Clinical and Research Reports (Jan 2024)

HIP1-ALK–Rearranged Lung Cancer in a Young Adult With BRAF V600E Mutation Detected After ALK Tyrosine Kinase Inhibitor Therapy: A Case Report

Aiko Ogimoto, MD,
Naoko Katsurada, MD, PhD,
Atsuhiko Yatani, MD,
Chihiro Mimura, MD,
Masatsugu Yamamoto, MD, PhD,
Motoko Tachihara, MD, PhD

Affiliations

Aiko Ogimoto, MD: Division of Respiratory Medicine, Department of Internal Medicine, Kobe University Graduate School of Medicine, Kobe, Japan
Naoko Katsurada, MD, PhD: Corresponding author. Address for correspondence: Naoko Katsurada, MD, PhD, Division of Respiratory Medicine, Department of Internal Medicine, Kobe University Graduate School of Medicine, 7-5-1 Kusunoki-cho, Chuo-ku, Kobe 650-0017, Japan.; Division of Respiratory Medicine, Department of Internal Medicine, Kobe University Graduate School of Medicine, Kobe, Japan
Atsuhiko Yatani, MD: Division of Respiratory Medicine, Department of Internal Medicine, Kobe University Graduate School of Medicine, Kobe, Japan
Chihiro Mimura, MD: Division of Respiratory Medicine, Department of Internal Medicine, Kobe University Graduate School of Medicine, Kobe, Japan
Masatsugu Yamamoto, MD, PhD: Division of Respiratory Medicine, Department of Internal Medicine, Kobe University Graduate School of Medicine, Kobe, Japan
Motoko Tachihara, MD, PhD: Division of Respiratory Medicine, Department of Internal Medicine, Kobe University Graduate School of Medicine, Kobe, Japan

Journal volume & issue: Vol. 5, no. 1
p. 100612

Abstract

Read online

HIP1-ALK is a relatively rare fusion pattern in ALK-rearranged NSCLC. Existing studies on the efficacy of ALK tyrosine kinase inhibitor (TKI) resistance mechanisms and treatment strategies in HIP1-ALK–rearranged lung cancer are limited. Here, we report the case of an 18-year-old man with HIP1-ALK–rearranged adenocarcinoma who developed BRAF V600E and V1180L mutations after ALK TKI therapy, in whom the administration of BRAF and MEK inhibitors was ineffective. Brigatinib was effective after chemotherapy with cytotoxic drugs. Development of effective treatments is desirable for rare variants of ALK-rearranged lung cancer after acquiring resistance to ALK TKIs.

Published in JTO Clinical and Research Reports

ISSN: 2666-3643 (Online)
Publisher: Elsevier
Country of publisher: United States
LCC subjects: Medicine: Internal medicine: Neoplasms. Tumors. Oncology. Including cancer and carcinogens
Website: https://www.journals.elsevier.com/jto-clinical-and-research-reports/

About the journal

Abstract

Keywords